Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to $40.6 million.

  • Viridian Therapeutics, Inc.\DE's Accumulated Expenses rose 1696.99% to $40.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.6 million, marking a year-over-year increase of 1696.99%. This contributed to the annual value of $45.7 million for FY2024, which is 8969.22% up from last year.
  • Per Viridian Therapeutics, Inc.\DE's latest filing, its Accumulated Expenses stood at $40.6 million for Q3 2025, which was up 1696.99% from $35.3 million recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Accumulated Expenses ranged from a high of $45.7 million in Q4 2024 and a low of $10.3 million during Q3 2021
  • Its 5-year average for Accumulated Expenses is $23.0 million, with a median of $21.4 million in 2023.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 36854.3% in 2021, then plummeted by 943.28% in 2022.
  • Viridian Therapeutics, Inc.\DE's Accumulated Expenses (Quarter) stood at $11.0 million in 2021, then soared by 70.87% to $18.8 million in 2022, then increased by 28.05% to $24.1 million in 2023, then soared by 89.69% to $45.7 million in 2024, then decreased by 11.15% to $40.6 million in 2025.
  • Its Accumulated Expenses stands at $40.6 million for Q3 2025, versus $35.3 million for Q2 2025 and $29.6 million for Q1 2025.